ロード中...
Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
Prostate cancer (PCa) is one of the most frequent tumor types in the male Western population. Early‐stage PCa and late‐stage PCa are dependent on androgen signaling, and inhibitors of the androgen receptor (AR) axis represent the standard therapy. Here, we studied in detail the global impact of daro...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7463324/ https://ncbi.nlm.nih.gov/pubmed/32333502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12693 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|